Skip to content
Sexuality – Lifestyle
Author:
InnoCare Pharma
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
May 28, 2026
InnoCare Announces Approval of Orelabrutinib in Australia
May 27, 2026
2026 ASCO | Pivotal Data of InnoCare’s Novel BCL2 Inhibitor Mesutoclax Released
May 22, 2026
InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
May 13, 2026
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren’s Syndrome in China
May 7, 2026
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
May 6, 2026
←
Previous Page
1
2
3